MITICURE for house Dust Mite Allergic Rhinitis Now Available in Japan

ALK

today announced that the sublingual allergy immunotherapy product MITICURE now will be available for prescription in Japan for adults and adolescents (12-64 years) who suffer from house dust mite allergic rhinitis. As of today, MITICURE(tm) has been placed on the Japanese National Health Insurance reimbursement list and will be launched in the beginning of December 2015.   MITICURE(tm) is the Japanese trade name of the sublingual allergy immunotherapy tablet licensed by ALK to Torii for Japan. MITICURE(tm) is indicated in adults and adolescents (12-64 years) for the treatment of allergic rhinitis caused by house dust mites. With the intention of obtaining approval for pediatric use (5-11 years), Torii is currently conducting a Phase III clinical trial involving approximately 400 patients.  Torii has issued a news release concerning the launch of MITICURE(tm) which can be found on http://www.torii.co.jp.  The product was recently approved in 11 European countries where it is expected to soon become available in the first markets under the trade name ACARIZAX(r) for the treatment of house dust mite allergic rhinitis and allergic asthma in adults (18-65 years).  The product is also being developed for a number